Australia's Pathkey.AI rises after upgrade in its AI clinical trial platform 

**Shares of Australia's Pathkey.AI PPKY rise as much as 20.8% to A$0.029, their highest since September 8

**Artificial intelligence company says development of its AI-powered clinical trials platform, TrialKey, now includes drug-level features such as molecular structure and pharmacokinetics,

**Says TrialKey's move beyond trial optimisation to AI-driven drug discovery will likely open new commercial and clinical applications

**Adds new features to enhance predictive accuracy and guide drug candidate design

**Around 1 mln shares change hands, 1.4x the 30-day average trading volume

**PKY last up 16.7%, bringing YTD gains to 47.4%